Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Merck CEO: 'I can't blame the media'
A triad of Merck news today, including one item about the news. We'll start with that: CEO Dick Clark (photo) worried publicly about the media at a Morgan Stanley conference yesterday. In response to a question about the negative bent to Merck coverage these days, Clark said Merck and Big Pharma as a whole need to "do a better job...I don't think we're aggressive enough in getting our stories out there." He also used his new buzz-phrase "trust deficit" to describe the cloud hanging over the industry. Pressed, he said, "I can't blame the media. I have to blame us."
That's quite a turnabout for Clark, who blamed "media hype" for misleading folks to an unfairly negative view of Vytorin, the combo cholesterol drug that delivered disappointing results in the now-infamous Enhance study.
Meanwhile, the company and FDA have agreed on a labeling update to RotaTeq, the infant vaccine to prevent rotavirus infection. The new label will include the report of one vaccinated infant's death from a bowel obstruction. Back in February 2007 the FDA warned that 28 infants developed intussusception after taking RotaTeq, but the rate of that condition didn't exceed what's commonly seen among un-vaccinated babies. Merck reiterated that conclusion in announcing the labeling change.
And finally, Merck is giving Vioxx users more time to cough up documents that show they took Vioxx and then had a heart attack or stroke. The new deadline is June 30, instead of May 1.
- see the item in the Wall Street Journal Health Blog
- check out the vaccine news at MarketWatch
- find the Vioxx update in the Daily Record
Related Articles:
Pharma CEOs mull industry "trust deficit"
Merck's Clark: Stay the course
Merck chief got 80% pay hike
Comments (1) | Post a comment
Comments
By vioxx victim | Posted 2:43pm | May 2, 2008
Since Merck is giving the Settlement plaintiffs more time to send in documents, why can't they do the same(give more time) to the plaintiffs who are not in the Settlement. They put so many restrictions on these plaintiffs that it is nearly impossible not to join the settlement. What a surprise huh!! Merck sold poison to patients and now is making it hard to sue them. Many people died from their Vioxx and had heart attacks and strokes. These are the true victims of a Company who only cared about making money and not about helping people with medication. The CEO(Gilmartin) should be held criminally liable for knowing that Vioxx was and is poison.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
